Depression

Understanding the Black Box Warning in Early Antidepressant Use

Khaled Hamed, PMHNP-C

Written Jun 24, 2026 · Updated Jun 24, 2026

Medically reviewed by: Khaled Hamed, PMHNP-C

Every antidepressant carries the FDA's most serious label, a "black box" warning, about a possible increase in suicidal thoughts in children, teenagers, and young adults during the early part of treatment. Seeing that on a medication you or your child is about to start is unsettling, and it deserves a clear, honest explanation, because the warning is one of the most misunderstood in medicine. It does not mean antidepressants cause suicide, and it does not mean you shouldn't take them. It's a reminder to watch closely at the start, when vigilance matters most, while keeping in mind that untreated depression is itself one of the most serious risks of all.

What does the black box warning actually say?

In 2004 the FDA added the boxed warning, expanded in 2007 to include young adults up to age 24, after clinical trials found a small increase in suicidal thoughts and behaviors, not in completed suicides, among people under 25 who started antidepressants compared with those given a placebo. The risk it describes is concentrated early, during the first weeks of treatment and after any dose change. For adults 25 and older the picture is different, with no such increase, and in older adults antidepressants appear protective. The label also states plainly that depression itself raises the risk of suicide.

Does the black box warning mean antidepressants cause suicide?

Read quickly, the warning can sound like "antidepressants cause suicide." That isn't what it says. It doesn't mean the medications don't work, and it doesn't mean young people shouldn't take them. The FDA's stated intent was to increase monitoring during the vulnerable early period, not to discourage appropriate treatment. Interpreted as a reason to avoid medication, the warning works against the very people it was meant to protect.

Why the early weeks matter

There's a reason the warning focuses on the beginning. As an antidepressant starts to take hold, energy and initiative can return before mood and hopelessness fully lift. For a small number of vulnerable people, that gap can be a riskier window. This is exactly why staying in close contact early, and after any dose change, is the safeguard the warning is really pointing at.

What to watch for

For anyone under 25 especially, in the first weeks and after dose changes, it's worth watching for worsening mood or hopelessness, new or worsening thoughts of self-harm, agitation, severe restlessness, irritability, trouble sleeping, or any marked change in behavior. For young people, having family or caregivers watching alongside makes a real difference. If any of these appear, contact the prescriber promptly. If there are thoughts of self-harm or it feels like a crisis, call or text 988, the Suicide and Crisis Lifeline, right away, or call 911 in an emergency.

The bigger picture

Here's the part that often gets lost. Depression left untreated carries serious dangers of its own, including to safety. Research in the years after the warning suggests that when its wording frightened families and clinicians away from treatment, antidepressant use among young people fell and suicidal behavior appears to have risen, the opposite of what was intended. Researchers continue to debate the details, but the core message holds: the safest approach is treatment paired with careful monitoring, not avoidance. For most young people with depression, the benefit of treatment, watched closely, outweighs the risk.

What this means for you

If you or your child is starting an antidepressant, expect closer check-ins early on, keep the lines of communication wide open, never stop abruptly, and take any warning signs seriously rather than waiting. That combination, treatment plus vigilance, is the safest path, and it's what the warning was always meant to encourage.

If you're weighing whether to start an antidepressant, or worried about someone who has, that's exactly the kind of thing to talk through with a clinician. Book your first evaluation and we can look at it together.

By the numbers

Each figure links to its primary source.

under-25, early treatment; not completed suicides
The FDA boxed warning (2004, expanded in 2007 to young adults up to age 24) reflects a small increase in suicidal thoughts and behaviors, not completed suicides, in people under 25 early in antidepressant treatment.Source: FDA; Frontiers in Psychiatry, 2019
reduced treatment, rising youth suicidal behavior
Research after the warnings found reduced antidepressant treatment among youth alongside increased suicide-related outcomes, opposite to the warnings' monitoring intent.Source: Health Affairs systematic review, 2024

Frequently asked questions

Does the black box warning mean antidepressants cause suicide?

No. It reflects a small increase in suicidal thoughts and behaviors - not completed suicides - in people under 25 early in treatment, seen in clinical trials. Its purpose is closer monitoring at the start, not avoiding treatment.

Who does the warning apply to?

Children, adolescents, and young adults up to age 24, especially during the first weeks of treatment and after dose changes. For adults 25 and older there's no such increase, and in older adults antidepressants appear protective.

Why is the early period riskier?

As an antidepressant begins working, energy and initiative can return before mood and hopelessness fully lift. For a small number of vulnerable people, that gap can be a higher-risk window, which is why close early monitoring matters.

What should I watch for when starting an antidepressant?

Worsening mood or hopelessness, new or worsening thoughts of self-harm, agitation, severe restlessness, irritability, sleep problems, or marked behavior changes, especially in the first weeks. Report them to the prescriber promptly; in a crisis, call or text 988.

Should the warning stop someone from taking an antidepressant?

Not by itself. Untreated depression carries serious risks, and for most young people the benefit of treatment with close monitoring outweighs the risk. The warning is about vigilance, not avoidance.

What's the safest way to start an antidepressant for a young person?

Closer check-ins early on, open communication, family or caregiver awareness, taking warning signs seriously, and never stopping abruptly. Treatment paired with monitoring is the approach the warning was meant to encourage.

References

  1. Chu A, Wadhwa R. Selective Serotonin Reuptake Inhibitors. StatPearls (NCBI Bookshelf) - includes the FDA boxed warning on suicidality in patients under 25 and the emphasis on early monitoring.
  2. US Food and Drug Administration. Suicidality in Children and Adolescents Being Treated With Antidepressant Medications - the boxed warning and its monitoring guidance.
  3. Friedman RA. Antidepressants' Black-Box Warning - 10 Years Later. New England Journal of Medicine. 2014;371:1666-1668 - the FDA weighed a small risk against proven benefits; unintended consequences of the warning.
  4. Soumerai SB, Lu CY, et al. Intended and Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review - reduced treatment and increased suicide-related outcomes following the warnings. Health Affairs. 2024.
  5. Fornaro M, et al. The FDA 'Black Box' Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? - monitoring intent, the under-25 focus, and the high risk of untreated depression. Frontiers in Psychiatry. 2019;10:294.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. It does not establish a provider–patient relationship. Always consult a qualified healthcare provider for diagnosis and treatment.